This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
Miltenyi Biotec
product type :
antibody
product name :
IRF-7 pS477/pS479 Antibody, anti-human, PE, REAfinity™
catalog :
130-104-749
quantity :
30 tests in 300 µL
price :
110 USD
clonality :
monoclonal
host :
human
conjugate :
PE
clone name :
REA310
reactivity :
human
application :
immunohistochemistry, immunocytochemistry
citations: 3
Reference |
---|
Sgarbanti M, Marsili G, Remoli A, Orsatti R, Battistini A. IRF-7: new role in the regulation of genes involved in adaptive immunity. Ann N Y Acad Sci. 2007;1095:325-33 pubmed
|
Smith E, Marie I, Prakash A, Garcia Sastre A, Levy D. IRF3 and IRF7 phosphorylation in virus-infected cells does not require double-stranded RNA-dependent protein kinase R or Ikappa B kinase but is blocked by Vaccinia virus E3L protein. J Biol Chem. 2001;276:8951-7 pubmed
|
product information
MB Cataloge Number :
130-104-749
Catalog Number :
130-104-749
Product Name :
IRF-7 pS477/pS479 Antibody, anti-human, PE, REAfinity™
Product Type :
Primary antibodies, Recombinant antibodies
Host Species :
recombinant human IgG1
Clonality :
monoclonal
Conjugation :
PE
Antigen Modification :
IRF-7 pS477/pS479
Clone Name :
REA310
Isotype :
REA Control Antibody (I), human IgG1
Size :
30 tests in 300 µL
US List Price :
110 USD
Product Description :
Identification and enumeration of IRF-7 pS477/pS479+ cells by flow cytometry
ALTnames :
IRF7, IMD39, IRF-7H, IRF7A, IRF7B, IRF7C
Specificity :
human
Concentration :
1:11
Uses :
For research use only
Application Summary :
Intracellular flow cytometry, MICS (MACSima Imaging Cyclic Staining), Immunofluorescence, Immunohistochemistry
Storage :
Store protected from light at 2–8 °C. Do not freeze.
company information
Miltenyi Biotec
Friedrich-Ebert-Strae 68
51429 Bergisch Gladbach
51429 Bergisch Gladbach
macs@miltenyibiotec.com
https://www.miltenyibiotec.com1 800 FOR MACS
headquarters: Germany
questions and comments